#cash runway
7 stories
Curis Cash Runway Drives Investor Test
Curis' cash runway and clinical progress determine investor confidence after Q2 2026 earnings.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Innate Pharma Q2 Earnings Highlights
Innate Pharma secures $75m Sobi deal for cancer drug.
Yahoo Finance · 1m
Inventiva H1 Results: Cash Runway and NATiV3 at Center
Inventiva's cash runway and NATiV3 trial results drive investor focus after weak H1 earnings.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Lunai Bioworks Cash Runway at Risk
Lunai Bioworks' earnings hinge on cash runway and platform proof.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Nanobiotix Cash Runway Meets Clinical Progress
Nanobiotix's cash runway until 2029 supports JNJ-1900 trials amid clinical progress.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Addex Therapeutics Cash Runway at Risk
Addex Therapeutics' cash runway shrinks as it regains GABAB rights and faces funding pressure.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
LENZ Therapeutics VIZZ Launch Tests Cash Runway
LENZ Therapeutics' VIZZ eye drop launch reveals if early prescription traction can cover launch costs and scale quickly.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m